<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18097">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871297</url>
  </required_header>
  <id_info>
    <org_study_id>12712A</org_study_id>
    <secondary_id>2008-005356-25</secondary_id>
    <nct_id>NCT02871297</nct_id>
  </id_info>
  <brief_title>Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age</brief_title>
  <official_title>Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent
      patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™)
      diagnosis of MDD
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Safety evaluation based on adverse events, paediatric adverse event rating scale (PAERS), clinical safety laboratory tests (including reproductive hormones), vital signs, weight, height, Tanner score, menstrual cycle, ECG, and Columbia Suicide Severity Rating Scale (C-SSRS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CDRS-R total score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Children Depression Rating Scale - Revised version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse (CDRS-R ≥40 with a history of 2 weeks of clinical deterioration)</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>Children Depression Rating Scale - Revised version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first loss of remission (CDRS-R &lt;28 with a history of 2 weeks of clinical deterioration)</measure>
    <time_frame>Up to Week 26</time_frame>
    <description>Children Depression Rating Scale - Revised version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGI-S score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Clinical Global Impression - Severity of Illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-I score</measure>
    <time_frame>Week 26</time_frame>
    <description>Clinical Global Impression - Global Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children (7-11 years): Change in BRIEF using the Global Executive Composite score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Behaviour Rating Inventory of Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children (7-11 years): Change in BRIEF using the Metacognition Index</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Behaviour Rating Inventory of Executive Function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adolescents (12-18 years): Change in BRIEF-SR using the Global Executive Composite score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Behaviour Rating Inventory of Executive Function - Self-report version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adolescents (12-18 years): Change in BRIEF-SR using the Metacognition Index</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Behaviour Rating Inventory of Executive Function - Self-report version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CGAS score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Children's Global Assessment Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in in PedsQL VAS score</measure>
    <time_frame>Change from baseline to Week 26</time_frame>
    <description>Pediatric Quality of Life Inventory Present Functioning Visual Analogue Scales</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily dosing of vortioxetine (oral tablets) for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.</description>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Brintellix (R)</other_name>
    <other_name>Lu AA21004</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is a male or female child aged ≥7 and &lt;12 years or adolescent aged ≥12
             and ≤18 years in the lead-in study (12709A and 12710A).

          -  The patient must have completed Study 12709A or 12710A (Visit 12, Completion Visit)
             immediately prior to enrolment into this extension study.

          -  The patient had a primary diagnosis of MDD at entry in study 12709A or 12710A,
             diagnosed according to DSM-5™.

          -  The patient is indicated for long-term treatment with vortioxetine according to the
             clinical opinion of the Investigator.

          -  For patients aged ≥7 and ≤17 years at the Baseline visit; the patient is able to
             understand the Informed Assent Form, and parent(s)/legal representative(s) are able
             to read and understand the Informed Consent Form.

          -  For patients who turned 18 years during the lead-in study 12710A; the patient has
             signed the Informed Consent Form.

        Exclusion Criteria:

          -  The patient has been diagnosed with another psychiatric disorder (for example
             mania,bipolar disorder, schizophrenia or any psychotic disorder) during study 12709A
             or 12710A.

          -  The patient has an attention-deficit/hyperactivity disorder (ADHD) that requires a
             pharmacological treatment other than a stimulant medication.

        Other protocol-defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US1054</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1023</name>
      <address>
        <city>Targovishte</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BG1025</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EE1007</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FR1017</name>
      <address>
        <city>Elancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HU1023</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LV1002</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LV1008</name>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1002</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL1051</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RU1048</name>
      <address>
        <city>Tonnel'nyy</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ES1044</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 17, 2017</lastchanged_date>
  <firstreceived_date>August 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adolescent</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
